CALGB 100801 (Alliance): A Phase II Multi-Center NCI Cooperative Group Study of the Addition of Azacitidine (AZA) to Reduced-Intensity Conditioning (RIC) Allogeneic Transplantation for High Risk Myelodysplasia (MDS) and Older Patients with Acute Myeloid Leukemia (AML): Results of a “test dose” Strategy to Target Busulfan Exposure
Ravi Vij(Washington University in St. Louis), Steven M. Devine(National Marrow Donor Program), Eva Hoke(Leukemia Research Foundation), Kouros Owzar(Duke University), Richard M. Stone(Dana-Farber Cancer Institute), Tsiporah B. Shore(Cornell University), Aaron P. Rapoport(University of Maryland, Baltimore), Thomas C. Shea(University of North Carolina at Chapel Hill), William Blum(The Ohio State University), Paula N. Friedman(University of North Carolina at Chapel Hill), Vera Hárs
Cited by 7
Related Papers
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
|New England Journal of Medicine|2021|1.6k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k